Q&A: Legend Biotech CEO on whether Carvykti can meet expectations

Q&A: Legend Biotech CEO on whether Carvykti can meet expectations

Submitted by admin on April 15, 2024 - 11:16am
Source: 
Medical Marketing and Media
News Tags: 
Legend Biotech
Carvykti
mutliple myeloma
JNJ
Headline: 
Q&A: Legend Biotech CEO on whether Carvykti can meet expectations
snippet: 

With the multiple myeloma drug’s climb from fifth- to second-line therapy, Carvykti uptake is set to expand. Legend Biotech CEO Ying Huang discusses timing of a crucial supply bump.

Do Not Allow Advertisers to Use My Personal information